RANKL/RANK control Brca1 mutation-driven mammary tumors

Cell Research

Volumn 26, Issue 7, 2016, Pages 761-774

  Sigl, Verena ^a   Owusu Boaitey, Kwadwo ^b   Joshi, Purna A ^c   Kavirayani, Anoop ^a   Wirnsberger, Gerald ^a   Novatchkova, Maria ^a   Kozieradzki, Ivona ^a   Schramek, Daniel ^d,e   Edokobi, Nnamdi ^b   Hersl, Jerome ^f   Sampson, Aishia ^f   Odai Afotey, Ashley ^g   Lazaro, Conxi ^h   Gonzalez Suarez, Eva ^h   Pujana, Miguel A ^h   Heyn, Holger ^h   Vidal, Enrique ⁱ   Cruickshank, Jennifer ^c   Berman, Hal ^c   Sarao, Renu ^a   Ticevic, Melita ^a   Uribesalgo, Iris ^a   Tortola, Luigi ^a   Rao, Shuan ^a   Tan, Yen ^j   Pfeiler, Georg ^j   Lee, Eva Yhp ^k   Bago Horvath, Zsuzsanna ^j   Kenner, Lukas ^j,l   Popper, Helmuth ^m   Singer, Christian ^j   Khokha, Rama ^c   Jones, Laundette P ^f   Penninger, Josef M ^a   more..

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g Department of Obstetrics Gynecology   (United States)

^h BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

ⁱ UNIVERSITAT POMPEU FABRA   (Spain)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

^m MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

BRCA1; inherited breast cancer; mammary progenitor cells; RANK; RANKL

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR ALPHA; HYBRID PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROGESTERONE RECEPTOR; PROTEIN P53; RANK-FC; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DNA DAMAGE; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; GENETICS; GENOTYPE; HUMAN; METABOLISM; MOUSE; PATHOLOGY; STEM CELL; TRANSGENIC MOUSE;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; DNA DAMAGE; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENOTYPE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, PROGESTERONE; RECOMBINANT FUSION PROTEINS; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84973167255     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2016.69     Document Type: Article

References (46)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
2. Widschwendter M, Rosenthal AN, Philpott S , et al. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol 2013; 14:1226-1232.
3. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006; 314:1467-1470.
4. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-2424.
5. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 1999; 397:315-323.
6. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765
7. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-831.
8. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
9. Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 2011; 22:188-194.
10. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103:41-50.
11. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature 2010; 465:803-807.
12. Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010; 465:798-802.
13. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010; 468:98-102.
14. Gonzalez-Suarez E, Jacob AP, Jones J, et al RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468:103-107.
15. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008; 105:1680-1685.
16. Hanada R, Leibbrandt A, Hanada T, et al. Central control of fever and female body temperature by RANKL/RANK. Nature 2009; 462:505-509.
17. Berton TR, Matsumoto T, Page A, et al. Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues. Oncogene 2003; 22:5415-5426.
18. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007; 104:12111-12116.
19. Lin SC, Lee KF, Nikitin AY, et al. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 2004; 64:3525-3532.
20. Pfefferle AD, Herschkowitz JI, Usary J, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol 2013; 14:R125.
21. Couch FJ, Wang X, McGuffog L, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013; 9:e1003212.
22. Gaudet MM, Kuchenbaecker KB, Vijai J, et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet 2013; 9:e1003173.
23. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals loci associated with risk of fracture. Nat Genet 2012; 44:491-501.
24. Rivadeneira F, Styrkarsdottir U, Estrada K, et al. Genetic Factors for Osteoporosis (GEFOS) Consortium, Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009; 41:1199-1206.
25. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70.
26. Cordero A, Pellegrini P, Sanz-Moreno A, et al. Rankl impairs lactogenic differentiation through inhibition of the prolactin/Stat5 pathway at midgestation. Stem Cells 2016; 34:1027-1039.
27. Lee HJ, Gallego-Ortega D, Ledger A, et al. Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development 2013; 140:1397-1401.
28. Obr AE, Grimm SL, Bishop KA, Pike JW, Lydon JP, Edwards DP. Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol 2013; 27:1808-1824.
29. Fan S, Wang J, Yuan R, Rosen EM, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284:1354-1356.
30. Ma Y, Katiyar P, Jones LP, et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 2006; 20:14-34.
31. Jones LP, Li M, Halama ED, et al. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene 2005; 24:3554-3562.
32. Dvinge H, Git A, Graf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013; 497:378-382.
33. Srinivas S, Watanabe T, Lin CS, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 2001; 1:4.
34. Pencik J, Schlederer M, Gruber W, et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun 2015; 6:7736.
35. Rudmann D, Cardiff R, Chouinard L, et al. Proliferative and nonproliferative lesions of the rat and mouse mammary, Zymbals, preputial, and clitoral glands. Toxicol Pathol 2012; 40:7S-39S.
36. Cardiff RD, Anver MR, Gusterson BA, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000; 19:968-988.
37. Frech MS, Halama ED, Tilli MT, et al. Deregulated estrogen receptor a expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res 2005; 65:681-685.
38. Eirew P, Stingl J, Raouf A, et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 2008; 14:1384-1389.
39. Stingl J, Emerman JT, Eaves CJ. Enzymatic dissociation and culture of normal human mammary tissue to detect progenitor activity. Methods Mol Biol 2005; 290:249-263.
40. Chen X, Iliopoulos D, Zhang Q, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 2014; 508:103-107.
41. Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer 2011;11:708-718.
42. Joshi PA, Waterhouse PD, Kannan N, et al. RANK signaling amplifies WNT-responsive mammary progenitors through R-SPONDIN1. Stem Cell Reports 2015; 5:31-44.
43. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8:R76.
44. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012; 28:882-883.
45. Chen X, Li J, Gray WH, et al. TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform 2012; 11:147-156.
46. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.